Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 69% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($228.6M FCF) & 60.2% Gross Margin
Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling
Even with a 58/100 (D+) score, TRLV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 57.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.19) or 200D SMA ($8.82) invalidates the momentum regime and cuts Target Base ($10.60) toward Bear Floor ($8.27).
Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) slipped -0.19% to $10.60, trading at 69% of its 52-week range ($4.62 – $13.28). Stretched risk/reward at current multiples (13% return on capital) under elevated 10-year interest-rate pressure.
U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TRLV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TRLV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) ranks #225 by composite RQD confidence (58/100, grade D+) and #258 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, TRLV leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRLV
ACTIVE
Trulieve Cannabis Corp. Subordinate Voting Shares | D+ | 58/100 | — | 60.2% | 12.8% | -0.19% | $2.04B | Benchmark Subject |
| CRON Cronos Group Inc. Common Share | D+ | 52/100 | — | 42.8% | -4.5% | +0.30% | $1.24B | /cron-vs-trlv → |
| RGC Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -5.64% | $3.40B | /rgc-vs-trlv → |
| DFTX Definium Therapeutics Inc. | D+ | 52/100 | — | — | -32.2% | -0.37% | $5.10B | /dftx-vs-trlv → |
| TLRY Tilray Brands Inc. | E | 32/100 | — | 28.4% | -3.9% | -1.86% | $390.2M | /tlry-vs-trlv → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) reported GAAP revenue of $1.18B (-0.4% vs. FY2024 revenue of $1.19B , and +4.6% cumulative change since FY2023) , GAAP net income of -$116.4M, operating cash flow of $272.8M, and free cash flow of $228.6M (+53.6% YoY). On the balance sheet, TRLV closed FY2025 with $2.70B in total assets against $0 in total debt (Altman Z-Score: 1.12, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.18B | -$116.4M | $272.8M | $228.6M | $2.70B | — |
| FY2024 (FY) | 2024-12-31 | $1.19B | -$155.1M | $271.5M | $148.9M | $2.87B | — |
| FY2023 (FY) | 2023-12-31 | $1.13B | -$526.8M | $201.8M | $201.8M | — | — |
As of 2026-11-01, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.60 (-0.19% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #225 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
TRLV last traded at $10.60 (-0.19% on volume of 1,034,372 shares), positioning the stock -5.27% below its 50-day simple moving average ($11.19) and +20.18% above its 200-day simple moving average ($8.82). Across its 52-week range of $4.62 to $13.28, TRLV sits at the 69.1% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.28 to $11.92).
Why TRLV Stock slipped -0.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (13% return on capital) under elevated 10-year interest-rate pressure.